Enterprise HL7 / FHIR Terminology Engine
Universal Clinical Codes & Terminology Search
Search, verify, and inspect standardized LOINC, SNOMED CT, ICD-10-CM, RxNorm, and CPT clinical codes with native HL7 FHIR R4 resource mappings.
Showing 20 of 12623 codes
Per page:
Need to map or validate codes in bulk?
Cross-reference up to 1,000 ICD-10, LOINC, and CPT records simultaneously in memory with our free utility.
| Code Value | Display Description | Code System & OID | FHIR Resource | Category | Status | Actions |
|---|---|---|---|---|---|---|
|
0322U
|
Neurology (autism spectrum disorder [ASD]) quantitative measurements of 14 acyl carnitines and microbiome-derived metabolites liquid chromatography with tandem mass spectrometry (LC-MS/MS) plasma results reported as negative or positive for risk of metabolic subtypes associated with ASD
|
CPT
2.16.840.1.113883.6.12
|
Procedures | Procedures | Active |
|
|
0323T
|
Removal of subcutaneous implantable defibrillator pulse generator with replacement of subcutaneous implantable defibrillator pulse generator only
|
CPT
2.16.840.1.113883.6.12
|
Procedures | Procedures | Active |
|
|
0323U
|
Infectious agent detection by nucleic acid (DNA and RNA) central nervous system pathogen metagenomic next-generation sequencing cerebrospinal fluid (CSF) identification of pathogenic bacteria viruses parasites or fungi
|
CPT
2.16.840.1.113883.6.12
|
Procedures | Procedures | Active |
|
|
0324T
|
Removal of subcutaneous defibrillator electrode
|
CPT
2.16.840.1.113883.6.12
|
Procedures | Procedures | Active |
|
|
0324U
|
Oncology (ovarian) spheroid cell culture 4-drug panel (carboplatin doxorubicin gemcitabine paclitaxel) tumor chemotherapy response prediction for each drug
|
CPT
2.16.840.1.113883.6.12
|
Procedures | Procedures | Active |
|
|
0325T
|
Repositioning of subcutaneous implantable defibrillator electrode and/or pulse generator
|
CPT
2.16.840.1.113883.6.12
|
Procedures | Procedures | Active |
|
|
0325U
|
Oncology (ovarian) spheroid cell culture poly (ADP-ribose) polymerase (PARP) inhibitors (niraparib olaparib rucaparib velparib) tumor response prediction for each drug
|
CPT
2.16.840.1.113883.6.12
|
Procedures | Procedures | Active |
|
|
0326T
|
Electrophysiologic evaluation of subcutaneous implantable defibrillator (includes defibrillation threshold evaluation induction of arrhythmia evaluation of sensing for arrhythmia termination and programming or reprogramming of sensing or therapeutic parameters)
|
CPT
2.16.840.1.113883.6.12
|
Procedures | Procedures | Active |
|
|
0326U
|
Targeted genomic sequence analysis panel solid organ neoplasm cell-free circulating DNA analysis of 83 or more genes interrogation for sequence variants gene copy number amplifications gene rearrangements microsatellite instability and tumor mutational burden
|
CPT
2.16.840.1.113883.6.12
|
Procedures | Procedures | Active |
|
|
0327T
|
Interrogation device evaluation (in person) with analysis review and report includes connection recording and disconnection per patient encounter; implantable subcutaneous lead defibrillator system
|
CPT
2.16.840.1.113883.6.12
|
Procedures | Procedures | Active |
|
|
0327U
|
Fetal aneuploidy (trisomy 13 18 and 21) DNA sequence analysis of selected regions using maternal plasma algorithm reported as a risk score for each trisomy includes sex reporting if performed
|
CPT
2.16.840.1.113883.6.12
|
Procedures | Procedures | Active |
|
|
0328T
|
Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis; implantable subcutaneous lead defibrillator system
|
CPT
2.16.840.1.113883.6.12
|
Procedures | Procedures | Active |
|
|
0328U
|
Drug assay definitive 120 or more drugs and metabolites urine quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) includes specimen validity and algorithmic analysis describing drug or metabolite and presence or absence of risks for a significant patient-adverse event per date of service
|
CPT
2.16.840.1.113883.6.12
|
Procedures | Procedures | Active |
|
|
0329T
|
Monitoring of intraocular pressure for 24 hours or longer unilateral or bilateral with interpretation and report
|
CPT
2.16.840.1.113883.6.12
|
Procedures | Procedures | Active |
|
|
0329U
|
Oncology (neoplasia) exome and transcriptome sequence analysis for sequence variants gene copy number amplifications and deletions gene rearrangements microsatellite instability and tumor mutational burden utilizing DNA and RNA from tumor with DNA from normal blood or saliva for subtraction report of clinically significant mutation(s) with therapy associations
|
CPT
2.16.840.1.113883.6.12
|
Procedures | Procedures | Active |
|
|
0330U
|
Infectious agent detection by nucleic acid (DNA or RNA) vaginal pathogen panel identification of 27 organisms amplified probe technique vaginal swab
|
CPT
2.16.840.1.113883.6.12
|
Procedures | Procedures | Active |
|
|
0331U
|
Oncology (hematolymphoid neoplasia) optical genome mapping for copy number alterations and gene rearrangements utilizing DNA from blood or bone marrow report of clinically significant alterations
|
CPT
2.16.840.1.113883.6.12
|
Procedures | Procedures | Active |
|
|
0332U
|
Oncology (pan-tumor) genetic profiling of 8 DNA-regulatory (epigenetic) markers by quantitative polymerase chain reaction (qPCR) whole blood reported as a high or low probability of responding to immune checkpoint-inhibitor therapy
|
CPT
2.16.840.1.113883.6.12
|
Procedures | Procedures | Active |
|
|
0333T
|
Visual evoked potential screening of visual acuity automated
|
CPT
2.16.840.1.113883.6.12
|
Procedures | Procedures | Active |
|
|
0333U
|
Oncology (liver) surveillance for hepatocellular carcinoma (HCC) in high-risk patients analysis of methylation patterns on circulating cell-free DNA (cfDNA) plus measurement of serum of AFP/AFP-L3 and oncoprotein des-gamma-carboxy-prothrombin (DCP) algorithm reported as normal or abnormal result
|
CPT
2.16.840.1.113883.6.12
|
Procedures | Procedures | Active |
|
Healthcare Terminology & FHIR R4 Interoperability
Standardized coding guidelines governed by CodesForMD
In HL7 FHIR R4, discrete clinical findings and laboratory measurements are encapsulated inside
Observation resources. Diagnostic terms and problem list entries are represented within Condition resources, while surgical and therapeutic acts map to Procedure. CodesForMD adheres to official US Core and International FHIR Implementation Guides.
An OID is an internationally standardized dotted-decimal identifier (e.g.
2.16.840.1.113883.6.1 for LOINC) registered with HL7 and ISO. OIDs ensure unambiguous identification of terminology authorities when exchanging clinical messages across heterogeneous EHR, LIS, and PACS systems.
Yes. You can visit our platform's administrative ingestion and export engine or contact our team to obtain batch files of standardized codes.